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Factor VIII-von Willebrand factor (FVIIIvWF) complex, a
molecule involved in coagulation, can be physically associated
withosteoprotegerin (OPG).OPG is an anti-osteoclastic protein
and a soluble receptor for the proapoptotic protein TRAIL
(tumor necrosis factor-related apoptosis-inducing ligand), sug-
gesting a potential role of FVIIIvWF complex in bone and can-
cer biology.We, thus, assessed the effects of FVIIIvWFcomplex
on osteoclastogenesis and cell survival. We first evidenced that
FVIIIvWF complex inhibited RANKL-induced osteoclastogen-
esis and enhanced the inhibitory effect ofOPG. Interestingly,we
revealed by surface plasmon resonance that FVIIIvWF complex
bound toRANKL,whereas recombinant FVIII and vWFdid not.
Bymodeling,we showed that theOPGbinding domain to theA1
domain of vWF was closely located and partially overlapped to
its binding site to RANKL. Then, we demonstrated that
FVIIIvWF complex cancelled the inhibitory activity of OPG on
TRAIL-induced apoptosis and characterized interactions
between these molecules. The present work evidenced a direct
activity of FVIIIvWF complex on osteoclasts and on induced
cell apoptosis, pointing out its potential involvement in physio-
logical bone remodeling or in bone damages associated with
severe hemophilia and cancer development.
Themolecular triadosteoprotegerin (OPG)3/RANK/RANKLis
a crucial parameter of bone biology. Receptor activator of
nuclear factor B ligand (RANKL), a member of the tumor
necrosis factor family, is mainly expressed by osteoblasts in the
bone microenvironment and acts as a pro-resorption factor (1,
2); RANKL binds to its receptor RANK expressed at the cell
surface of osteoclast precursors and induces osteoclastic differ-
entiation and maturation, leading to bone resorption (3, 4).
OPG, also mainly produced by osteoblasts, is a soluble decoy
receptor for RANKL, preventing the binding of RANKL to
RANK and, thus, inhibiting osteoclastogenesis (5–7). Bone
turnover is tightly controlled by theOPG/RANK/RANKL triad,
and any change in the balance OPG/RANKL leads to patholog-
ical conditions (7). OPG is also a receptor for tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) (8, 9), a cyto-
kine that is able to induce a rapid cancer cell death by apoptosis
(9–11). Interestingly, the binding of OPG to TRAIL completely
inhibits TRAIL-induced cytotoxicity (8). OPG possesses anti-
apoptotic properties and, therefore, could be considered as a
pro-tumoral agent.
Factor VIII is a plasma glycoprotein mainly synthesized by
hepatocytes but also by kidney, sinusoidal endothelial cells, and
in small amounts by lymphatic tissues (12). Factor VIII is one of
the main coagulation factors and allows the completion of the
coagulation process. Factor VIII circulates in plasma in a non-
covalent complex with the von Willebrand factor (FVIIIvWF
complex). Themost well known genetic disease associatedwith
Factor VIII is hemophilia A, which shows an X-linked inherit-
ance (13). A second important disease associated with low Fac-
tor VIII levels is von Willebrand disease, a bleeding disorder
(14, 15). Patients suffering from von Willebrand disease have
primary hemostasis defects leading tomucocutaneous bleeding
or spontaneous deep tissue bleeding, such as in hemophilia A,
or both (14). Bleeding diseases could be associated with differ-
ent bone phenotypes. For instance, in a murine model of plate-
let-type von Willebrand disease, a significant increase of bone
mass and cortical thickness due to a reduction of the number of
osteoclasts is observed (16). In contrast, various case reports
suggest that children suffering from severe hemophilia have
more risks for low bone density and osteopenia/osteoporosis,
preferentially caused by physical inactivity and leading to loss of
joint function, shorter height, lower weight, and muscle atro-
phy (17, 18).
von Willebrand factor is a multimeric protein containing
many binding domains for various proteins such as the D-D3
domain, which binds Factor VIII (FVIII) (19), and the A1
domain, which can bind different proteins such as the platelet
glycoprotein Ib (20), heparin (21), and snake venom toxins
(bitiscetin (22) and botrocetin (23)). Recently, it has been
shown that the vWF is physically complexed to OPG (through
the A1 domain) within the Weibel-Palade bodies and also in
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plasma, revealing a possible modulatory role of OPG in hemo-
stasis (24, 25). The aim of the present study was to characterize
the effects of FVIIIvWF complex on osteoclastogenesis and
cancer cell survival and then interactions between complex
FVIIIvWF complex and three members of tumor necrosis fac-
tor cytokine/cytokine receptor family: OPG, RANKL, and
TRAIL. The data obtained demonstrated that FVIIIvWF com-
plex binds to OPG and RANKL and, thus, indirectly partici-
pates in bone biology. Indeed, we first demonstrated that the
FVIIIvWF complex inhibits RANKL-induced osteoclastogen-
esis. Second, we demonstrated that the FVIIIvWF complex
abolished the inhibitory effectofOPGonTRAIL-inducedapop-
tosis, revealing a key role of FVIIIvWF complex in cancer
development.
EXPERIMENTAL PROCEDURES
Osteoclast Differentiation Assay—Generation of osteoclasts
from murine RAW 264.7 cells was performed as previously
described (26) in the presence of recombinant human RANKL
(100 ng/ml) (kindly provided byAmgen Inc.), humanOPG (100
ng/ml) (R&D systems), FVIIIvWF complex purified from
plasma (ProSpec), or recombinant FVIII (Octocog , kindly
provided by CSL Behring) (1 or 2 units/ml). Generation of oste-
oclasts from human CD14 monocytes was described previ-
ously (26). Briefly, purified CD14 cells were cultured in
-minimum essential mediumwith 10% fetal calf serum and 25
ng/ml humanmacrophage colony-stimulating factor (R&Dsys-
tems). After 3 days of culture, 100 ng/ml RANKL, 100 ng/ml
OPG, and 1 unit/ml FVIII or FVIIIvWF were added. Multinu-
cleated cells formed with three nuclei, and more were counted
after TRAP staining (Sigma).
Cell Proliferation—Human osteosarcoma cell lines MG63 and
SaOS2 aswell as the Ewing’s sarcoma cell lineTC71were cultured
in Dulbecco’s modified Eagle’s medium containing 10% fetal calf
serum. MG63 and SaOS2 cells were seeded at 500 cells/well in
96-well plates, andTC71 cellswere seeded at 1500 cells/well. Cells
were treated with 50–100 ng/ml TRAIL (R&D Systems), 50–100
ng/ml OPG, and 1 unit/ml FVIIIvWF complex for 72 h. After the
culture period, cell viability was determined by a cell proliferation
reagent assay kit using sodium 3-(1-(phenylaminocarbonyl)-3,4-
tetrazolium)-bis(4-methoxy-6-nitro)benzenesulfonic acid hydrate
(XTT Roche Applied Science).
Hoechst Staining and Caspase-3 Activity—Cell death was
monitored microscopically after Hoechst 33258 (Sigma) stain-
ing. MG63, SaOS2, and TC71 cells were seeded in a 96-multi-
well plate and treated or not with TRAIL (50 ng/ml), OPG (50
ng/ml), and FVIIIvWF complex (1 unit/ml) for 16 h, stained
with 10 g/ml Hoechst reagent for 20 min at 37 °C, and then
observed under UV microscopy (DMRXA; Leica, Germany).
Caspase-3 activity was assessed on 10 l of total treated cell
lysates using the kit CaspACE assay system, fluorometric (Pro-
mega) following the manufacturer’s recommendations. Results
are expressed in arbitrary units and are corrected for protein
content.
Surface Plasmon Resonance Binding Assays—Experiments
were carried out on aBIAcore 3000 instrument (BIAcore).OPG
(1 g/ml in 5 mM maleate, pH 6.0), RANKL (2 g/ml in 5 mM
maleate, pH 5.75), and TRAIL (10 g/ml in 10 mM acetate, pH
5.5) were covalently immobilized to the dextran matrix of a
CM5 sensor chip (BIAcore) at a flow rate of 5 l/min. Immobi-
lization levels ranging from 300 RU for OPG and 400 RU for
RANKL to 700 RU for TRAIL were obtained. vWF (Hemato-
logic Technologies) was immobilized on a C1 sensor chip at
2000 RU. Binding assays were performed at 25 °C in 10 mM
Hepes buffer, pH 7.4, containing 0.15 M NaCl and 0.005% P20
surfactant (HBS-P buffer, BIAcore) or in a pH 6.5 buffer con-
taining 20 mM Bis-Tris and 10 mM CaCl2 at a flow rate of 30
l/min for immobilized-OPG and 20 l/min for immobilized
RANKL and immobilized-TRAIL. OPG Kd values for vWF and
FVIIIvWFwere determined using single cycle kinetics, starting
with 25 nM OPG or with 300 nM FVIIIvWF, then 1⁄2 dilutions.
For binding analysis over the immobilized RANKL or immobi-
lized-TRAIL chip, binding of OPG alone or preincubated for
120 min with different concentrations of FVIIIvWF complex
was performed for 4min at a flow rate of 20l/min followed by
dissociation for 2.5 min. The resulting sensorgrams were fitted
using BiaEval 4.1 software (BIAcore). For Kd calculations, the
following molecular masses were used: recombinant FVIII, 330
kDa; FVIIIvWF complex, 540 kDa.
ELISA Assay—FVIIIvWF complex was coated at 1 unit/ml
on a 96-well plate overnight at room temperature. OPG or
RANKL (bothwere tested at 500, 100, and 10 ng/ml) were incu-
bated for 2 h at room temperature. After 2 washes with PBS,
Tween 0.05%, the revelation of the binding of OPG or RANKL
to FVIIIvWF complex was performed using a specific biotinyl-
ated antibody against each molecule (anti-OPG was from R&D
systems and anti-RANKL fromPeprotech). Streptavidin conju-
gated to horseradish peroxidase (R&D systems) was incubated
for 20 min, then the revelation solution (Promega) was added
for 20 min, and the reaction was stopped with sulfuric acid
solution. The absorbance at 450 nm was measured using a
microplate reader (Victor II, PerkinElmer Life Sciences).
Modeling Analysis—To design OPG and RANKL, sequences
were retrieved from the Universal Protein resource. Each pro-
tein was subjected to BLAST searches on the organism species
(Homo sapiens) and on the organism classification (Mammalia,
Vertebrata) (27). These sequences were further analyzed using
multiple sequence alignments to extract the most conserved
residues (28). The multiple alignments were manually adjusted
using Jalview (29). Human OPG and human RANKL models
were built using Modeler 9v5 (30) from these refined align-
ments, respectively, using substructure of DR5 (PDB code
1D4V) (31) and mouse RANKL (PDB code 1IQA) (32). All
resulting models were assessed using the Protein Health mod-
ule of Discovery Studio 2.1 (Accelrys Inc.). Alignment of the A1
domain of vWF on OPG has been realized as described below.
Structural figures were produced with VMD (33) and rendered
using Pov-Ray.
OPG, RANKL, and TRAIL Effect on the Coagulation Cascade—
Plasma of a healthy donor was drawn on 0.109 M buffered cit-
rate.OPG,TRAIL, andRANKLwere added to the plasma at 100
ng/ml. Primary hemostasis was tested using PFA 100 automate
(Siemens). The Quick time was determined using the reagent
RecombiPlasTin (Instrumentation Laboratory) on the ACL
TOP automate (Instrumentation Laboratory). The activated
partial thromboplastin time (aPTT) was tested using Trini-
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CLOTThrombin Time reagent (Trinity Biotech) onACLTOP.
The thrombin time was tested using thrombin (Siemens) on
ACL TOP. The FVIII/C method was based on the aPTT. This
assay was performed using FVIII-deficient plasma (Biopep), an
aPTT reagent with kaolin as contact phase activator (CK Prest,
Diagnostica Stago, France), and an ACL TOP coagulometer.
Statistical Analysis—The mean S.D. was calculated for all
conditions and compared by analysis of variance with Bonfer-
roni multiple comparisons test as the post hoc test. Differences
relative to a probability of two-tailed p 0.05 were considered
significant.
RESULTS
FVIIIvWF Inhibits Murine and Human Osteoclast Differen-
tiation Induced by RANKL—The impact of the FVIIIvWF com-
plex on osteoclastogenesis was first examined using the cellular
modelRAW264.7.After5daysof culturewith100ng/mlRANKL,
RAW 264.7 cells differentiated into multinucleated cells. As
expected, 50ng/mlOPGinhibited theRANKL-inducedosteoclas-
togenesis by 47% (p  0.01) (Fig. 1A). Surprisingly, 2 units/ml
FVIIIvWF complex inhibited RANKL-induced osteoclastogen-
esis by 42% (p 0.01), whereas 1 unit/ml FVIIIvWF complex had
no effect on RANKL-induced osteoclastogenesis (Fig. 1A). Fur-
thermore, when 2 units/ml FVIIIvWFcomplexwere added to the
culture medium in the presence of OPG, the inhibition of oste-
oclastogenesis was significantly stronger than that observed with
OPG alone. Indeed, the inhibition of RANKL-induced osteoclas-
togenesis reached 65% in the presence of a mixture OPG,
FVIIIvWF complex compared with 47% with OPG alone (p 
0.05). The recombinant FVIII alone had no effect on RANKL-in-
duced osteoclastogenesis of RAW264.7 cells (data not shown).
To ascertain the effect of FVIIIvWF complex on osteoclas-
togenesis, we next generated osteoclasts from human CD14
purified from total peripheral blood mononuclear cells upon
macrophage colony-stimulating factor and RANKL activation
(26). As shown in Fig. 1, B and C, and similarly to RAW 264.7
cells, 1 unit/ml FVIIIvWF complex significantly inhibited by
30% the RANKL-induced osteoclastogenesis of CD14 cells
(p  0.05) (Fig. 1C). Furthermore, 1 unit/ml FVIIIvWF com-
plex reinforced the OPG inhibitory activity on RANKL-in-
duced osteoclastogenesis (p 0.05) (Fig. 1C). In accordance
with the RAW 264.7 cells, the recombinant FVIII alone had
no effect on RANKL-mediated osteoclastogenesis (data not
shown).
RANKL Binds to FVIIIvWF Complex Similarly to OPG—To
explore the molecular mechanism underlying the effect of the
FVIIIvWF complex on RANKL-induced osteoclastogenesis and
the possible synergistic effect ofOPGandFVIIIvWFcomplex, we
investigated the molecular interactions between RANKL, OPG,
FVIIIvWFcomplex, recombinantFVIII, andvWFby surfaceplas-
mon resonance. It has been determined that OPG and vWF are
physically associated in Weibel-Palade bodies of endothelial cells
and also in the plasma (24, 25). Thus, we first immobilized vWF
and confirmed that the interaction between OPG and vWF
depends on the biochemical environment (25). In fact, the binding
of OPG to immobilized-vWF occurred only with 20mM Bis-Tris,
pH 6.5, and not with 10 mM Hepes, pH 7.4 (Fig. 2A), and the dis-
sociation constant obtained wasKd 3.51 109 M (Fig. 2B). Then
FIGURE 1. FVIIIvWF complex inhibits RANKL-induced osteoclastogen-
esis. A, RAW 264.7 cells were cultured for 5 days in the presence or not of 100
ng/ml human RANKL (hRANKL), 100 ng/ml OPG, and 1 or 2 units/ml FVIIIvWF
complex. After May Gru¨nwald/Giemsa staining. B, purified human CD14
monocytes were cultured for 15 days in the presence of 25 ng/ml human
macrophage colony-stimulating factor and 100 ng/ml human RANKL and 1
unit/ml FVIIIvWF. TRAP coloration was performed at the end of the culture
period. C, purified human CD14monocytes were cultured for 15 days in the
presence of 25 ng/ml humanmacrophage colony-stimulating factor and 100
ng/ml human RANKL with or without 50 ng/ml OPG and 1 unit/ml FVIIIvWF.
Multinucleated TRAP-positive cells were counted under a lightmicroscope. A
and C, results are expressed as the number of multinucleated cells (more
than three nuclei) per well; each value represents the mean  S.D. All
experiments were performed independently three times in triplicate. *,
p  0.05, **, p  0.01.
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we revealed that in the pH 7.4 buffer FVIIIvWF complex was also
able tobindto immobilized-OPG,whereas recombinantFVIIIwas
not (Fig. 2C). Furthermore,usinga singlecyclekinetic assay, theKd
of OPG for FVIIIvWF complex was 7.19 108 M (Fig. 2D). The
binding of OPG to the FVIIIvWF complex was also confirmed
by ELISA assay. As shown in Fig. 2E, OPG can bind in a
dose-dependent manner to the FVIIIvWF complex previ-
ously coated. Taken together, these results revealed that the
interaction between OPG and the FVIIIvWF complex
occurred through the vWF.
To explore the putative mode of ligand-receptor binding, we
modeled the OPG-RANKL interaction using constructs ob-
tained from crystallographic coordinates of homologous
proteins TRAIL-DR5 complex as described by Cheng et al.
(34). We confirmed that OPG-RANKL binding model is
closely related to TRAIL-DR5 binding mode (data not
FIGURE 2. The interaction between OPG and the FVIIIvWF complex occurred through the vWF. A, OPG binds to immobilized-vWF chip in specific
biochemical conditions. Binding assays were performed using 2 different buffers (pH 7.4 or 6.5) as described under “Experimental Procedures.” B, determina-
tion of the KdofOPG for vWFusing a single cycle kinetic assay is shown.OPGwas injected over immobilized vWF in pH6.5 buffer at 25 nM and then 1⁄2 dilutions.
C, in thepH7.4buffer, FVIIIvWFcomplex, butnot recombinant FactorVIII, binds toOPG. FVIIIvWFcomplex (50units/ml) or recombinant FactorVIII (50units/ml)
was injected at a flow rate of 30 l/min over the immobilized-OPG sensor chip for 5 min, and the dissociation was monitored for 10 min. D, determination of
the Kd of OPG for FVIIIvWF complex in pH 7.4 buffer using a single cycle kinetic assay is shown. FVIIIvWF complexwas injected over immobilized-OPG starting
at 300 nM and then 1⁄2 dilutions. E, OPG (500, 100, and 10 ng/ml) bound to the coated FVIIIvWF complex (1 unit/ml) using an ELISA assay is shown. Results are
expressed using arbitrary units. F, modeling of the interactions between OPG (green), RANKL (gray), and the A1 domain of vWF (yellow) is shown. OPG has the
same orientation in the three illustrations. The right illustration is an overlay of left andmiddle illustrations.G, shown is a representation of the binding domains
involved in the interaction OPG-RANKL and OPG-vWF. OPG amino acids involved for the bindingwith RANKL are schematized in black, and those involved for
the binding with vWF are schematized in yellow.
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shown). The data obtained clearly showed that the OPG
binding domain to A1 domain of vWF is closely located and
partly overlaps to its binding site to RANKL (Fig. 2F). Indeed,
the interface shape consists of two anchoring points on OPG
for RANKL by amino acids 68, 69, 82, and amino acids
88–91, 111, and 116–120, whereas the contact surface is a
continuum for A1 domain of vWF to OPG (amino acids
62–69 and 82–89) (Fig. 2G).
FIGURE 3.Complex FVIIIvWF can bind to RANKL andOPGprevents its binding. A, in the pH 7.4 buffer, FVIIIvWF complex, but not recombinant Factor VIII,
binds to RANKL. FVIIIvWF complex (50 units/ml) or recombinant Factor VIII (50 units/ml) was injected at a flow rate of 10l/min over the immobilized RANKL
sensor chip for 5 min, and the dissociation was monitored for 10 min. B, shown is RANKL (500, 100, and 10 ng/ml) bound to the coated FVIIIvWF complex (1
unit/ml) using an ELISA assay. Results are expressed in arbitrary units. C, FVIIIvWF complex increases the binding of OPG to RANKL. OPG was incubated with
increasing concentrations of FVIIIvWF complex for 2 h before the injection to immobilized RANKL.D, FVIIIvWF complex, OPG, and RANKL can form a tripartite
complex. Human RANKL (5 g/ml) was injected to immobilized OPG with a flow rate of 20 l/min, then the FVIIIvWF complex was injected. Schematic
explanations are represented in c and d.
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The binding of FVIIIvWF complex to immobilized RANKL
was then investigated in the pH 7.4 buffer. Surprisingly,
FVIIIvWF complex was able to bind to immobilized RANKL
(response of 150 RU), whereas recombinant FVIII was not (Fig.
3A). However, when using an immobilized-vWF sensor chip,
no binding was observed whatever the biochemical parameters
used (20mMBis-Tris, pH6.5, or 10mMHepes, pH7.4) (data not
shown). As for the binding of OPG to the FVIIIvWF complex,
we performed an ELISA assay using a coating of FVIIIvWF
complex. As shown in Fig. 3B, RANKL was able to bind to
FVIIIvWF complex in a dose-dependent manner, confirming
the results obtained by surface plasmon resonance experi-
ments. Thus, the present data demonstrated for the first time
the capacity of FVIIIvWF complex to bind RANKL. However,
in contrast toOPG, for which the interaction with this complex
is done via the vWF, our results suggested that the tridimen-
sional structure of the FVIIIvWF complex is mandatory for its
interactionwithRANKL.To further explore the involvement of
the FVIIIvWF complex in the RANKL/OPG interactions, the
effect of a preincubation of OPG (100 ng/ml) and increasing
concentrations of FVIIIvWF complex for 2 hwas assessed. The
pre-formed FVIIIvWF complexOPG complex was then
injected over the immobilized RANKL (Fig. 3C). This experi-
ment revealed that the pre-formed complex FVIIIvWF/OPG
did not prevent the binding ofOPG toRANKLor the binding of
FVIIIvWF to RANKL. Furthermore, the binding of OPG was
higher in the presence of FVIIIvWF complex than without this
complex. These results suggest that the FVIIIvWF complex, by
binding to RANKL or OPG, induced somemodifications in the
three-dimensional structure of OPG, RANKL, or FVIIIvWF,
resulting in a higher affinity between OPG and RANKL and
then potentially increasing its biological activity. Such hypoth-
esis was supported by the synergistic effect of OPG-FVIIIvWF
complex observed on RAW 264.7 cells (Fig. 1A). Similarly, Fig.
3D showed that FVIIIvWF complex was still able to bind
RANKL or OPG even if RANKL had already been bound to
immobilized-OPG, demonstrating that these three molecules
can interact together without interfering the binding of one to
another (see Fig. 3, c and d, for schematic explanations). The
same results were observed using immobilized vWF; indeed, a
FIGURE 4. TRAIL binds to FVIII without affecting TRAIL/OPG interactions. A, recombinant Factor VIII and FVIIIvWF complex bind to immobilized-TRAIL.
Recombinant Factor VIII (50 units/ml) or FVIIIvWF complex (50 units/ml) were injected at a flow rate of 30 l/min over the immobilized-TRAIL for 2 min
association. B, recombinant Factor VIII bound to TRAIL does not interfere the binding of TRAIL to immobilized-OPG. 50 units/ml recombinant Factor VIII was
preincubated with TRAIL for 2 h at room temperature. The complex formed was then injected to immobilized-OPG. C, FVIIIvWF complex inhibits the binding
ofOPG to TRAIL. FVIIIvWFcomplexwas incubatedwithOPG for 2h at room temperature; thenewcomplex formedwas then injected at a flow rate of 30l/min
for 2 min over immobilized-TRAIL. D, schematic representation of plasmon resonance experiments a, b, and c summarized respectively A, B, and C.
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pre-formed complex OPG/RANKL was able to bind to immo-
bilized vWF in the sameway as OPG alone (see the supplemen-
tal figure).
TRAIL Binds to FVIII without Affecting TRAIL/OPG
Interactions—OPG is not only a decoy receptor for RANKL but
also acts as soluble receptor for TRAIL and, thus, inhibits its
proapoptotic activity (8, 10, 11). To determine whether or not
the FVIIIvWF complex could affect the complex OPG/TRAIL,
TRAIL has been immobilized on a sensor chip, and the capacity
of FVIIIvWF complex to bind to TRAIL was analyzed. In con-
trast to the previous experiments with OPG and RANKL, both
FVIIIvWF complex and recombinant FVIII were able to bind
to immobilized TRAIL (Fig. 4A and summarized in Fig. 4D).
Furthermore, as for OPG binding to immobilized-vWF, only
specific biochemical conditions of 20 mM Bis-Tris, pH 6.5,
allowed the binding of TRAIL to immobilized vWF (no binding
with 10 mM Hepes, pH 7.4) (data not shown). We confirmed
that TRAIL bound to immobilized-OPG and showed that the
complex formed byTRAIL and recombinant FVIII was still able
to bind similarly to OPG (Fig. 4B). To further explore the
involvement of the FVIIIvWF complex in the OPG/TRAIL
interactions, the effect of a preincubation of OPG and increas-
ing concentrations of FVIIIvWF has been investigated. What-
ever the concentration of FVIIIvWF complex used to form a
complex with OPG, all these combinations completely inhib-
ited the binding of OPG to TRAIL (Fig. 4C and summarized in
Fig. 4D). These results suggested that the binding domains of
OPG to vWF and TRAIL is very closed, and one molecule
bound to OPG can then block the binding sites of the second.
To investigate the relevance of this inhibition in a biological
experiment, we performed a viability assay on the humanosteo-
sarcoma cell line MG63 sensitive to TRAIL-induced apoptosis.
As shown in Fig. 5A, the ability of TRAIL to induce MG63 cell
death (75%, p 0.01) was prevented by the addition of OPG.
In contrast, when 1 unit/ml FVIIIvWF complex was added to
the culture medium, OPG was not able to prevent the capacity
of TRAIL to induceMG63 cell death (60%,p 0.05). Further-
more, the apoptotic effect of TRAIL was confirmed even in the
presence of FVIIIvWF complex and OPG. Nucleus fragmenta-
tion was observed in MG63 (Fig. 5B). In the same manner of
50 ng/ml TRAIL, the combination TRAIL  FVIIIvWF com-
plexOPG induced nucleus fragmentation, as the cells exhibited
a characteristic kidney-like form with condensed chromatin
clumps compared with control cells. Moreover, TRAIL induced
a significant increase of caspase-3 activity inMG63cells (p0.01)
(Fig. 5C) which was significantly reduced in the presence of OPG.
But the caspase-3 activity was not decreased by OPG when
FVIIIvWF complex was added (p  0.05). The same results of
viability,Hoechst staining, and caspase-3 activationwere obtained
usingothercell lines sensitive toTRAIL-inducedapoptosis suchas
the human osteosarcoma cell line SaOS2 and the human Ewing’s
sarcomacell lineTC71 (datanot shown).Thus, thesedata revealed
that the inhibitory effect ofOPGonTRAIL-inducedapoptosis can
be reversed by FVIIIvWF complex and then evidenced the role of
FVIIIvWF complex in the control of cell death.
Recombinant Human OPG, RANKL, and TRAIL Do Not
Affect the Coagulation Cascade—Because of the different inter-
actions evidenced in our study between OPG, RANKL, TRAIL,
and the FVIIIvWF complex, we evaluated the potential impli-
cations of these three molecules on the coagulation cascade.
We demonstrated that 100 ng/ml OPG, RANKL, and TRAIL
have no effect on the following assays: primary hemostasis,
FIGURE 5. FVIIIvWF complex blocks the inhibitory effect of OPG on TRAIL-
inducedapoptosisonMG63cells.A, osteosarcomacell lineMG63wascultured
with100ng/mlTRAIL100ng/mlOPG1unit/mlFVIIIvWFcomplex.After72h
of culture, cell viability was determined by XTT assay. Results were expressed as
percentage of control. Experiments were performed at least three times (*, p
0.05). B, nuclear morphological changes induced by TRAIL, OPG, and FVIIIvWF
complexwere analyzed by Hoechst staining onMG63 cells. C, caspase-3 activity
was assessed on MG63 cells after 16 h of treatment with TRAIL, OPG, and
FVIIIvWF complex (*, p 0.05; **, p 0.01).
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Quick time, aPTT, thrombin time, and the FVIII/C method
based on the aPTT (data not shown).
DISCUSSION
FVIII associated with the vWF is a key protagonist of the
coagulation process as evidenced in patients suffering from
hemophilia A. Recent papers revealed the physical interaction
between vWF and OPG (24, 25), a powerful inhibitor of oste-
oclastogenesis and, therefore, of bone resorption (7). Although
severe hemophilia patients have also joint diseases, to our
knowledge there is no evidence of the effect of FVIIIvWF com-
plex on bone cells and especially on osteoclasts. The present
work demonstrates that FVIIIvWF complex binds to OPG and
RANKL and, thus, indirectly participates to bone biology. This
paper is, thus, the first evidence that FVIIIvWF complex inhib-
its RANKL-induced osteoclastogenesis. Furthermore, in a sec-
ond part of the manuscript, we also demonstrated for the first
time that the FVIIIvWF complex abolishes the inhibitory effect
of OPG on TRAIL-induced apoptosis, suggesting a potential
function of FVIIIvWF complex in cancer development (Fig. 6).
In two different models FVIIIvWF complex regulates oste-
oclastogenesis by inhibiting the pro-osteoclastic activity of
RANKL.Twodifferent effects can be involved in this inhibition;
the first way of inhibition occurs through a physical interaction
between FVIIIvWF complex and RANKL, leading to an inacti-
vation of RANKL, and the second potential effect is a synergic
effect of the FVIIIvWF complex with OPG. In fact, both mole-
cules inhibit RANKL-induced osteoclastogenesis by them-
selves, but their association in the culture medium increased
this inhibitory effect. However, different mechanisms could be
proposed. OPG could bind to the FVIIIvWF complex through
the vWF, and this complex could
increase the affinity of OPG to
RANKL, or the complex FVIIIvWF
could bind to both RANKL and
OPG, leading to a stronger inhibi-
tion of RANKL activity.
These interactions between
FVIIIvWF complex, OPG, and
RANKL point out their potential
involvement in bone and vascular
system (7). Indeed, the hallmark of
severe hemophilia is repeated
bleedings into joints and muscles
resulting in a severe and painful
inflammation of synovitis named
hemophilic synovitis (35, 36). How-
ever, the exact mechanism related
to blood-induced joint disease is not
precisely known even if somemech-
anisms are now settled. The pro-
cesses that occur at the early stages
of blood-induced joint disease asso-
ciated with infiltration of inflamma-
tory cells releasing high amounts of
inflammatory cytokines, enzymes
(36), proteins such as hemoglobin,
and an increase of intra-articular
pressure and synovial proliferation. The later stages are charac-
terized by a promotion of angiogenesis, cartilage cell apoptosis,
and subchondral bone destruction. Thus, hemophilic arthrop-
athy shares several biological featureswith rheumatoid arthritis
(37). Numerous studies in rheumatoid arthritis models have
produced evidence for a causal role of excessive RANKL activ-
ity in associated-bone loss (38). Indeed, RANKL levels were
concomitantly increased in inflamed joint leading to an
increase in the RANKL/OPG ratio, which appears positively
correlated with bone destruction and osteoclast activity (39).
The present data evidenced for the first time that FVIIIvWF
complex inhibits RANKL-induced osteoclastogenesis. More-
over FVIIIvWF complex did not abolish OPG activity on oste-
oclastogenesis but reinforced its activity in murine and human
models. In this context hemophilic arthritis may be associated
with an intra-articular inflammatory process concomitantly
with an increased osteoclastogenesis due to a deficiency of
FVIIIvWF complex.
OPG/RANK/RANKL triad constitutes a molecular bridge
spanning bonemetabolism, vascular biology, and immunity (7).
The first evidence linking the OPG/RANK/RANKL system to
the vessel biology has been provided by the vascular phenotype
ofOPG-deficientmice (40). Indeed,OPG-deficientmice exhib-
ited medial calcification of the aorta and renal arteries and not
of smaller vessels, suggesting that OPG and its molecular part-
ners may play a role in the long term-observed association
between osteoporosis and vascular calcification (40). OPG
physically associated with the vWF is localized in the Weibel-
Palade bodies of endothelial cells and is rapidly secreted in
response to inflammatory stimuli (24).More recently, in a case-
control study Bilora et al. (41) assessed the presence of athero-
FIGURE 6. Schematic representation describing the involvement of FVIIIvWF complex in coagulation
cascade, bone, and cancer biology. FVIIIvWF complex is one of the main complex involved in coagulation;
FVIII is released from vWF by the action of thrombin and becomes a cofactor for Factor IX to stimulate coagu-
lation cascade,whereas vWF is essential inplatelet activation. FVIIIvWFcomplex alsoplays amajor role inother
biological processes. Indeed, this complex inhibits RANKL-induced osteoclastogenesis by binding to RANKL
andalsoby increasing the anti-osteoclastic activity ofOPG. Furthermore, FVIIIvWFcomplexmaybe involved in
cell apoptosis (endothelial, bone, and cancer cells); through its binding to OPG, the FVIIIvWF complex inhibits
the OPG protective effect on TRAIL-induced apoptosis that occurs in inflammation and cancer disorders.
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sclerosis in 50 patients suffering from hemophilia and in 50
age-matched control individuals. Their results suggest that
hemophilia could protect against asymptomatic atherosclero-
sis. Overall, these observations strongly support that the
OPG/RANK/RANKL and FVIIIvWF systems constitute a
molecular cascade essential in the development of athero-
sclerotic lesions. Furthermore, our present work gives a bio-
logically direct relationship between the FVIIIvWF system
and osteoclastic cells, strengthening the interests of prophy-
laxis in young patients suffering from severe hemophilia.
Even if prophylaxis seems to be the best therapeutic option
for severe hemophilia A to prevent joint damages in evi-
dence-based medicine (42, 43), these results give a basic
explanation for the effect of prophylaxis in joint damage and
subchondral bone erosion prevention.
The second important result reported in our study is the
control of cell apoptosis by the FVIIIvWF complex. We
observed in vitro that OPG did not inhibit TRAIL-induced cell
apoptosis when FVIIIvWF complex was present in the culture
medium. Physical interactions between the FVIIIvWF com-
plex, OPG, and TRAIL were confirmed by surface plasmon res-
onance experiments. We showed that the FVIIIvWF complex
was able to bind to TRAIL, and then we demonstrated that,
when associated to OPG, FVIIIvWF complex prevented the
binding TRAIL/OPG, correlating the in vitro apoptosis exper-
iment. To our knowledge, the functional relationship between
Factor VIII and/or vWF and apoptosis has never been investi-
gated. TRAIL is a cytotoxic ligand that binds to type I trans-
membrane receptors (DR4 andDR5) possessing death domains
and which ultimately activates the caspase cascade, inducing
cell death (44). TRAIL also has two decoy receptors (DcR1,
DcR2) that lack a functional death domain and explain in part
the absence ofmassive apoptosis in cells that express functional
membrane receptor (45). However, normal and cancer cells
lacking these decoy receptors can escape to cell death through
the expression of OPG, which is able to block TRAIL transduc-
tion signaling (8). It is well established that the coagulation
cascade contributes to cancer development (46), and a clear
correlation between thrombosis and cancer progression has
been established. Indeed, tissue factor is up-regulated on both
tumor and host cells in cancer patients and initiates protease-
activated receptor-mediated cell signaling that leads to the pro-
duction of soluble cytokines and angiogenic growth factors
(47). More recently, Ho-Tin-Noe´ et al. demonstrated that
platelets support tumor vascular homeostasis by regulating the
stability of tumor vessels (48). Thus, tumor development ap-
pears as the equilibrium between cell proliferation and cell
death actively controlled by blood vessels and coagulation cas-
cade. By reversing the inhibitory effect of OPG on TRAIL-
induced apoptosis, FVIIIvWF may control tumor growth.
Hemophilia A has been recently reported after tumor resec-
tion in patients suffering from glioblastoma (49), and it has
been suggested that cancer cells could produce factor VIII-
like tumor antigens. Such hypothesis has been also strength-
ened by Franchini et al. (50), who recently reviewed the
acquired factor VIII inhibitors in oncohematology. If the origin
of such nonclassical antibodies against FVIII is not yet defined,
these autoantibodies may complicate the clinical course of the
malignancy (51). All these data associated with the present
work are in favor of a contribution of FVIIIvWF complex dur-
ing cancer disorders. Then the interaction between OPG-
TRAIL-FVIIIvWF complex may be involved in induced cell
apoptosis (endothelial, cartilage, bone, and tumor cells), which
is essential during angiogenesis associated with inflammation
and cancer disorders.
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